Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic age-related and life-threatening conditions, has selected Biorasi LLC as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.   
 
Biorasi has extensive experience in the management and execution of neurology clinical studies, and in phase I through IV trials in the U.S. and globally.
 
“Partnering with Biorasi for Longeveron’s next Phase 2 AD trial will help continue to advance the development of Lomecel-B for the treatment of Alzheimer’s disease,” said Kevin N. Ramdas, MD, MPH, Director, Medical Affairs at Longeveron. “We look forward to initiating the trial by year-end, or in the first quarter of 2022.”